Cargando…
A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats
A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC(50) = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhib...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372569/ https://www.ncbi.nlm.nih.gov/pubmed/28272302 http://dx.doi.org/10.3390/ijms18030553 |
_version_ | 1782518645617852416 |
---|---|
author | Xiang, Hongjun Han, Yaotian Zhang, Yuzhong Yan, Wenqiang Xu, Bing Chu, Fuhao Xie, Tianxin Jia, Menglu Yan, Mengmeng Zhao, Rui Wang, Penglong Lei, Haimin |
author_facet | Xiang, Hongjun Han, Yaotian Zhang, Yuzhong Yan, Wenqiang Xu, Bing Chu, Fuhao Xie, Tianxin Jia, Menglu Yan, Mengmeng Zhao, Rui Wang, Penglong Lei, Haimin |
author_sort | Xiang, Hongjun |
collection | PubMed |
description | A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC(50) = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhibition of the rebound of the viral replication rate. Furthermore, Oxy-Di-OA showed good performance of anti-HBV activity in vivo. Some studies showed that liver fibrosis may affiliate with HBV gene mutations. In addition, the anti-hepatic fibrosis activity of Oxy-Di-OA has not been studied. Therefore, we evaluated the protective effect of Oxy-Di-OA against carbon tetrachloride (CCl(4))-induced liver injury in rats. Daily intraperitoneally administration of Oxy-Di-OA prevented the development of CCl(4)-induced liver fibrosis, which was evidenced by histological study and immunohistochemical analysis. The entire experimental protocol lasted nine weeks. Oxy-Di-OA significantly suppressed the increases of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (p < 0.05). Furthermore, Oxy-Di-OA could prevent expression of transforming growth factor β1 (TGF-β1). It is worth noting that the high-dose group Oxy-Di-OA is superior to bifendate in elevating hepatic function. Compared to the model group, Oxy-Di-OA in the high-dose group and low-dose group can significantly reduce the liver and spleen indices (p < 0.05). The acute toxicity test showed that LD(50) and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73–798.73 mg/kg via intraperitoneal injection in mice, respectively. The LD(50) value of Oxy-Di-OA exceeded 2000 mg/kg via gavage in mice. In addition, a simple and rapid high performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated to study the pharmacokinetic characteristics of the compound. After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (C(max) = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively. |
format | Online Article Text |
id | pubmed-5372569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-53725692017-04-10 A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats Xiang, Hongjun Han, Yaotian Zhang, Yuzhong Yan, Wenqiang Xu, Bing Chu, Fuhao Xie, Tianxin Jia, Menglu Yan, Mengmeng Zhao, Rui Wang, Penglong Lei, Haimin Int J Mol Sci Article A novel hepatoprotective oleanolic acid derivative, 3-oxours-oleana-9(11), 12-dien-28-oic acid (Oxy-Di-OA), has been reported. In previous studies, we found that Oxy-Di-OA presented the anti-HBV (Hepatitis B Virus) activity (IC(50) = 3.13 µg/mL). Remarkably, it is superior to lamivudine in the inhibition of the rebound of the viral replication rate. Furthermore, Oxy-Di-OA showed good performance of anti-HBV activity in vivo. Some studies showed that liver fibrosis may affiliate with HBV gene mutations. In addition, the anti-hepatic fibrosis activity of Oxy-Di-OA has not been studied. Therefore, we evaluated the protective effect of Oxy-Di-OA against carbon tetrachloride (CCl(4))-induced liver injury in rats. Daily intraperitoneally administration of Oxy-Di-OA prevented the development of CCl(4)-induced liver fibrosis, which was evidenced by histological study and immunohistochemical analysis. The entire experimental protocol lasted nine weeks. Oxy-Di-OA significantly suppressed the increases of plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels (p < 0.05). Furthermore, Oxy-Di-OA could prevent expression of transforming growth factor β1 (TGF-β1). It is worth noting that the high-dose group Oxy-Di-OA is superior to bifendate in elevating hepatic function. Compared to the model group, Oxy-Di-OA in the high-dose group and low-dose group can significantly reduce the liver and spleen indices (p < 0.05). The acute toxicity test showed that LD(50) and a 95% confidence interval (CIs) value of Oxy-Di-OA were 714.83 mg/kg and 639.73–798.73 mg/kg via intraperitoneal injection in mice, respectively. The LD(50) value of Oxy-Di-OA exceeded 2000 mg/kg via gavage in mice. In addition, a simple and rapid high performance liquid chromatography-ultraviolet (HPLC-UV) method was developed and validated to study the pharmacokinetic characteristics of the compound. After single-dose oral administration, time to reach peak concentration of Oxy-Di-OA (C(max) = 8.18 ± 0.66 μg/mL) was 10 ± 2.19 h; the elimination half-life and area under the concentration-time curve from t = 0 to the last time of Oxy-Di-OA was 2.19 h and 90.21 μg·h/mL, respectively. MDPI 2017-03-06 /pmc/articles/PMC5372569/ /pubmed/28272302 http://dx.doi.org/10.3390/ijms18030553 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xiang, Hongjun Han, Yaotian Zhang, Yuzhong Yan, Wenqiang Xu, Bing Chu, Fuhao Xie, Tianxin Jia, Menglu Yan, Mengmeng Zhao, Rui Wang, Penglong Lei, Haimin A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats |
title | A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats |
title_full | A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats |
title_fullStr | A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats |
title_full_unstemmed | A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats |
title_short | A New Oleanolic Acid Derivative against CCl(4)-Induced Hepatic Fibrosis in Rats |
title_sort | new oleanolic acid derivative against ccl(4)-induced hepatic fibrosis in rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372569/ https://www.ncbi.nlm.nih.gov/pubmed/28272302 http://dx.doi.org/10.3390/ijms18030553 |
work_keys_str_mv | AT xianghongjun anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT hanyaotian anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT zhangyuzhong anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT yanwenqiang anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT xubing anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT chufuhao anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT xietianxin anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT jiamenglu anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT yanmengmeng anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT zhaorui anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT wangpenglong anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT leihaimin anewoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT xianghongjun newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT hanyaotian newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT zhangyuzhong newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT yanwenqiang newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT xubing newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT chufuhao newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT xietianxin newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT jiamenglu newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT yanmengmeng newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT zhaorui newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT wangpenglong newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats AT leihaimin newoleanolicacidderivativeagainstccl4inducedhepaticfibrosisinrats |